USPTO trademark

HYBRID DRUG

Under examinationUSPTOWord markClass 9Class 42Class 44

"HYBRID DRUG" is a word mark owned by Remepy Inc., filed at the USPTO on October 12, 2026. It is under examination and covers classes 9, 42 and 44.

Get this data via the API
Official USPTO record
HYBRID DRUG trademark as filed
As filed with the USPTO
Status
Under examination
Since October 12, 2026
Filed
October 12, 2026
Registered
Not yet
Expires
Not recorded
Application no.
50155679
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
3 classes
Ownership

Who owns HYBRID DRUG

The owner and representative on file with the office.

Owner

Remepy Inc.

New York, United States

Representative

Phillip Barengolts

Goods and services

What the mark covers

The products and services HYBRID DRUG is filed for, grouped by Nice class.

  • Downloadable computer software and downloadable mobile applications for use in connection with pharmaceutical treatment; Downloadable computer software and downloadable mobile applications for use as digital therapeutics, namely, software for delivering therapeutic interventions for the prevention, management and treatment of diseases and disorders, and alleviating symptoms and improving health conditions associated with diseases and disorders, either as a standalone treatment or in combination with pharmaceutical preparations; Downloadable computer software and downloadable mobile applications featuring video, images, and sound for use in medical-related physical, psychological and cognitive training and for assessing, tracking, and analyzing users' personal health and health-related data; Downloadable computer software and downloadable mobile applications featuring computer games, video, images, and sound intended for improving users' physical and mental condition for medical purposes; Downloadable computer software and downloadable mobile applications incorporating artificial intelligence for physical and mental training for medical purposes; Downloadable computer software and downloadable mobile applications for monitoring and managing patient medical information

  • Medical and pharmaceutical research and development services; Research and development of combination therapies integrating pharmaceutical preparations with digital therapeutics; Providing scientific research information related to medical treatment protocols incorporating digital therapeutics; design and development of computer software for use as digital therapeutics, including digital therapeutics designed for use in combination with pharmaceutical treatment; Providing temporary use of non-downloadable computer software featuring video, images, and sound for use in medical-related physical and mental training, for assessing, tracking, and analyzing users' personal health, and for use as digital therapeutics; Providing temporary use of non-downloadable computer game software for improving users' physical and mental abilities and condition for medical purposes; Providing temporary use of non-downloadable computer software using artificial intelligence for use in physical and mental training for medical purposes; Providing temporary use of non-downloadable computer software for monitoring and managing patient medical information; Providing temporary use of non-downloadable computer software for use as digital therapeutics, namely, software for delivering therapeutic interventions for the prevention, management and treatment of diseases and disorders, and for alleviating symptoms and improving health conditions associated with diseases and disorders, either as a standalone treatment or in combination with pharmaceutical preparations; Providing temporary use of non-downloadable computer software for supporting and complementing pharmaceutical treatment

  • Medical services; Medical consulting services, namely, advising and providing information to healthcare professionals and patients regarding medical conditions and treatments; providing medical information in the fields of the prevention, management and treatment of diseases and health conditions; providing medical information related to medical treatment protocols that incorporate the use of digital therapeutics; providing medical information via the internet; providing personal health information via the internet; health counseling services in the fields of disease management and health conditions; health care services, namely, treatment of human diseases and health conditions by using digital therapeutics, alone or in combination with pharmaceutical preparations

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Application filing receipt mailed
  2. New application office supplied data entered
  3. New application entered
FAQ

About HYBRID DRUG

Who owns the trademark "HYBRID DRUG"?

The USPTO trademark "HYBRID DRUG" (application 50155679) is owned by Remepy Inc.

What is the status of "HYBRID DRUG"?

Its status at the USPTO is: under examination.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull HYBRID DRUG and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_01a137f0-8baf-75de-890a-23d836c16e60
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_01a137f0-8baf-75de-890a-23d836c16e60",
  "object": "trademark",
  "mark_text": "HYBRID DRUG",
  "status": {
    "primary": "pending",
    "stage": "examining"
  },
  "office_code": "US",
  "application_number": "50155679",
  "filing_date": "2026-10-12",
  "nice_classes": [
    9,
    42,
    44
  ],
  "owners": [
    {
      "name": "Remepy Inc.",
      "entity_id": null
    }
  ]
}